NCT02507544View on ClinicalTrials.gov

A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 29, 2017

Study Completion Date

May 20, 2019

Conditions
CarcinomaAdvanced Cancer
Interventions
DRUG

TRX-818 capsules

Trial Locations (2)

49503

START Midwest, Grand Rapids

78229

South Texas Accelerated Research Therapeutics, LLC (START), San Antonio

All Listed Sponsors
lead

TaiRx, Inc.

INDUSTRY

NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter